Phenylketonuria Test

Reference Ranges
Phenylalanine
Adult ( > 16y) < 16.00 mg/24hrs
0 - 4 months 1.10 TO 1.50 mg/24hrs
Child (5 - 12y) 4.00 TO 16.50 mg/24hrs
Conditions

 

References

  1. ^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0. 
  2. ^ cite journal - author=Gonzalez, Jason; Willis, Monte S. - date=Feb. 2010 - title=Ivar Asbjorn Folling Discovered Phenylketonuria (PKU) - journal=lab medicine - volume=41 - number=2 - pages=118-119
  3. ^ Folling, A. (1934). "Ueber Ausscheidung von Phenylbrenztraubensaeure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitaet". Ztschr. Physiol. Chem. 227: 169–176. 
  4. ^ Centerwall, S. A. & Centerwall, W. R. (2000). "The discovery of phenylketonuria: the story of a young couple, two affected children, and a scientist.". Pediatrics 105 (1 Pt 1): 89–103. doi:10.1542/peds.105.1.89. PMID 10617710. http://pediatrics.aappublications.org/cgi/content/full/105/1/89. 
  5. ^ Mayo Clinic Staff (2007-12-20). "Phenylketonuria (PKU)". Mayo Clinic. http://www.mayoclinic.com/health/phenylketonuria/DS00514/DSECTION=1. Retrieved 2008-03-13. 
  6. ^ http://www.genenames.org Phenylalanine hydroxylase (PAH) gene summary, retrieved September 8, 2006
  7. ^ Oh, H. J., Park, E. S., Kang, S., Jo, I., Jung, S. C. (2004). "Long-Term Enzymatic and Phenotypic Correction in the Phenylketonuria Mouse Model by Adeno-Associated Virus Vector-Mediated Gene Transfer". Pediatric Research 56: 278–284. doi:10.1203/01.PDR.0000132837.29067.0E. PMID 15181195. http://www.pedresearch.org/cgi/content/full/56/2/278. 
  8. ^ Gibbs, Richard A.; Jeffrey Rogers, Michael G. Katze, Roger Bumgarner, George M. Weinstock, Elaine R. Mardis, Karin A. Remington, et al. (April 2007). "Evolutionary and Biomedical Insights from the Rhesus Macaque Genome". Science 316 (5822): 222–234. doi:10.1126/science.1139247. PMID 17431167. http://www.sciencemag.org/cgi/content/full/316/5822/222. Retrieved 2008-02-26. 
  9. ^ Surtees, R., Blau, N. (2000). "The neurochemistry of phenylketonuria". European Journal of Pediatrics 169: S109–13. doi:10.1007/PL00014370. PMID 11043156. 
  10. ^ Online 'Mendelian Inheritance in Man' (OMIM) 261640
  11. ^ Michals, K., Matalon, R. (1985). "Phenylalanine metabolites, attention span and hyperactivity". American Journal of Clinical Nutrition 42(2): 361–365. PMID 4025205. 
  12. ^ Pietz, J., Kreis, R., Rupp, A., Mayatepek, E., Rating, D., Boesch, C., Bremer, H. J. (1999). "Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria". Journal of Clinical Investigation 103: 1169–1178. doi:10.1172/JCI5017. PMID 10207169. http://www.jci.org/cgi/content/full/103/8/1169. 
  13. ^ Burton, BK; Kar S, Kirkpatrick P (2008). "Fresh from the Pipeline: Sapropterin". Nature Reviews Drug Discovery 7: 199–200. doi:10.1038/nrd2540. http://www.nature.com/nrd/journal/v7/n3/full/nrd2540.html. 
  14. ^ Michals-Matalon K (2008). "Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria". Expert Opin Investig Drugs 17 (2): 245–51. doi:10.1517/13543784.17.2.245. PMID 18230057. 
  15. ^ Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA et al. (2007). "The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study". Journal of Inherited Metabolic Disorders 30: 700–707. doi:10.1007/s10545-007-0605-z. PMID 17846916. http://www.nature.com/nrd/journal/v7/n3/full/nrd2540.html. 
  16. ^ Levy H, Burton B, Cederbaum S, et al. (2007). "Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment". Mol Genet Metab 92 (4): 287–291. doi:10.1016/j.ymgme.2007.09.017. PMID 18036498. 
  17. ^ Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FKet al. (2007). "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.". Lancet 370: 504–510. doi:10.1016/S0140-6736(07)61234-3. PMID 17693179. 
  18. ^ Lee P, Treacy E, Crombez E, et al. (2008). "Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria". Am J Med Genet 146A (22): 2851–2859. doi:10.1002/ajmg.a.32562. PMID 18932221. 
  19. ^ Lee, P.J., Ridout, D., Walker, J.H., Cockburn, F., (2005). "Maternal phenylketonuria: report from the United Kingdom Registry 1978–97". Archives of Disease in Childhood 90: 143–146. doi:10.1136/adc.2003.037762. PMID 15665165. .
  20. ^ Rouse, B., Azen, B., Koch, R., Matalon, R., Hanley, W., de la Cruz, F., Trefz, F., Friedman, E., Shifrin, H. (1997). "Maternal phenylketonuria collaborative study (MPKUCS) offspring: Facial anomalies, malformations, and early neurological sequelae.". American Journal of Medical Genetics 69 (1): 89–95. doi:10.1002/(SICI)1096-8628(19970303)69:1<89::AID-AJMG17>3.0.CO;2-K. PMID 9066890. 
  21. ^ lsuhsc.edu Genetics and Louisiana Families
  22. ^ DiLella, A. G., Kwok, S. C. M., Ledley, F. D., Marvit, J., Woo, S. L. C. (1986). "Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene". Biochemistry 25: 743–749. doi:10.1021/bi00352a001. PMID 3008810. 
  23. ^ www.rikshospitalet.no
  24. ^ Guldberg, P., Henriksen, K. F., Sipila, I., Guttler, F., de la Chapelle, A. (1995). "Phenylketonuria in a low incidence population: molecular characterization of mutations in Finland". J. Med. Genet 32: 976–978. doi:10.1136/jmg.32.12.976. PMID 8825928. 
  25. ^ http://emedicine.medscape.com/article/947781-overview
GT:0.793